The glucagon-like peptides: a double-edged therapeutic sword?
Perry
TracyAnn
T
Section of Drug Design and Development, Laboratory of Neurosciences, Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA. perryt@grc.nia.nih.gov
Greig
Nigel H
NH
D000595:Amino Acid Sequence; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism; D000077270:Exenatide; D005934:Glucagon / Q000737:chemistry / Q000494:pharmacology* / Q000502:physiology; D052216:Glucagon-Like Peptide 1; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology* / Q000502:physiology; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology; D011498:Protein Precursors / Q000737:chemistry / Q000494:pharmacology* / Q000502:physiology; D018027:Receptors, Glucagon / Q000819:agonists* / Q000096:biosynthesis; D014688:Venoms
C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007328:Insulin; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D018027:Receptors, Glucagon; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide